Early Supplementation with Branched-Chain Amino Acids Ameliorates Lipid Retention in Aortic Valves of ApoE-Knockout Mice.

Early BCAA intake significantly reduced lipid retention in the aortic valve of ApoE-knockout mice.

• BCAA supplementation dose was 55 mg/day, corresponding to a human equivalent dose of 13.5 g/day.
• The protective effect was observed when treatment was initiated early, at either 1 or 3 months of age, and continued until 12 months.
• Late BCAA supplementation (initiated at 6 months) did not produce the same significant reduction in lipid retention.
• The anti-atherogenic effect of BCAA was higher in male than in female ApoE-knockout mice.

Magnesium citrate supplementation decreased serum ionized calcium in ApoE-knockout mice.

• Magnesium citrate (MgCit) dose was 1.85 mg/day, corresponding to a human equivalent dose of 450 mg/day.
• The effect on ionized calcium was higher in male than in female mice.
• MgCit did not produce significant anti-atherogenic or anti-calcific effects in the aortic valve comparable to those of BCAA on lipid retention.
• Serum ionized calcium was evaluated at the 12-month time point.

Both BCAA and MgCit protective effects were higher in male than in female ApoE-knockout mice.

• The study used both male and female ApoE-knockout mice.
• Sex-based differences were observed for lipid retention reduction by BCAA and ionized calcium reduction by MgCit.
• This sex difference was noted across the evaluated endpoints including lipid retention in the aortic valve and serum ionized calcium levels.

Dual supplementation with human serum albumin (HSA) and magnesium citrate reduced serum calcification propensity in 68% of myocardial infarction patients.

• The clinical component of the study included 100 patients with myocardial infarction.
• The intervention tested whether HSA or MgCit could decrease serum calcification propensity.
• Dual supplementation with HSA and MgCit reduced serum calcification propensity in 68% of cases.
• Serum calcification propensity was used as a surrogate measure to assess potential cardiovascular risk reduction.

The timing of BCAA supplementation initiation was critical, with early initiation (1 or 3 months) being necessary for significant lipid retention reduction.

• Treatment was initiated at either 1, 3, or 6 months of age in separate experimental groups.
• All animals were evaluated at the 12-month time point.
• Significant reduction in aortic valve lipid retention was achieved only with early supplementation (from 1 or 3 months of age).
• Late supplementation starting at 6 months did not produce the same significant protective effects, suggesting a critical window for intervention.

The study evaluated lipid retention and calcium deposition in the aortic valve, lipid burden in the aorta, and serum ionized calcium as primary endpoints in ApoE-knockout mice.

• Male and female ApoE-knockout mice were used as an atherosclerosis model.
• All endpoints were assessed at the 12-month time point regardless of when supplementation was initiated.
• Four endpoints were assessed: lipid retention in aortic valve, calcium deposition in aortic valve, lipid burden in aorta, and serum ionized calcium.
• The study design allowed comparison of both supplement types across three initiation time points and both sexes.